An investigative treatment for Porphyromonas gingivalis bacteria, which cause gum disease, was associated with reductions in blood markers of inflammation as well as ApoE protein fragments in the spinal fluid of people with mild to moderate Alzheimer's disease, according to a small trial presented at the Alzheimer's Association annual meeting. A larger clinical trial is underway, and a vaccine for the bacterium is also being developed.
Treatment for oral bacteria reduces Alzheimer's disease marker
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.